Browsing Tag

CTX130

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT)…

Eli Pacheco Sep 28, 2022 0

ZUG, Switzerland and BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for…

Health

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of…

Eli Pacheco Jun 11, 2022 0

-70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) at Dose Level 3 (DL3) and above; clinical…

Health

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70…

Eli Pacheco May 13, 2022 0

ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based…